3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Cholangiocarcinoma
4
Neoplasm Metastasis
2
Carcinoma, Transitional Cell
2
Acrocephalosyndactylia
2
Stomach Neoplasms
1
Oligodendroglioma
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
22
Bevacizumab
10
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Irinotecan
5
Carmustine
4
fluorodopa F 18
3
Topotecan
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiosurgery
3
Magnetic Resonance Imaging
3
Congresses as Topic
3
Carboplatin
3
Aminolevulinic Acid
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
ribociclib
2
poly ICLC
2
fluoromisonidazole
2
carmustine, poliferprosan 20 drug combination
2
cabozantinib
2
Vorinostat
2
TIC10 compound
2
Re-Irradiation
2
Radiotherapy, Intensity-Modulated
2
Panobinostat
2
O(6)-benzylguanine
2
Melphalan
2
Lomustine
2
Lacosamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Glioma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts